Abstract 134P
Background
Cancer cells exhibit heightened basal levels of responses to DNA breaks, accumulating DNA polymerases family (DNA-pol) as repair protein, thereby increasing DNA mutation and neoantigens. Based on this, we investigated the potential of DNA-pol as an immunotherapy biomarker and its underlying mechanism.
Methods
We conducted a pan-cancer analysis of DNA-pol gene dysregulation in 6366 samples. Normal fibroblast, cancer-associated fibroblast, and CD8+ T cells were cultured from cancer patients (3 esophagus, 5 lung, 5 renal, and 3 liver cancer), then treated them with PD-L1 inhibitor or overexpressing TERT for RNA-seq and proteomics. 996 multiple cancer cases with ICIs were collected to test biomarker efficiency. A phase II clinical trial is evaluating our biomarker prospectively.
Results
We defined a distinct signature score of DNA-pol genes upregulated in cancer (DNA-pol-up) and linked to worse prognosis (HR=1.2). DNA-pol-up program dysregulation led to immune processes alteration and was related to upstream activation of TERT signaling (z-score=3.6) in ingenuity pathway analysis and linked to immunologically active tumors by recruiting CD8+ T cell and downregulating CAF. DNA-pol-up score was elevated in PD-L1-treated CAF and TERT-overexpressed CD8+ T cell, in MSI-H cancer, also related to more neoepitope peptides, TMB (Rho=0.54), cancer stemness (Rho=0.78), and tumor purity (Rho=0.29). Cancers that activate this program carried distinct genomic profiles with PIK3CA, KRAS, and TP53 mutations. This signature was an independent predictor for ICIs response (OR=2.52), even outperforming cytolytic activity, MSI, TMB (OR=0.9). In 12 clinical trial datasets, this signature could stratify the responding patients (maxAUC=0.762). In our phase II clinical trial, 34 liver cancer were enrolled with 3-year follow-up, it also has a satisfactory performance in predicting the ORR (AUC=0.699) and classifies mortality rate (HR=2.3).
Conclusions
Our findings identify a distinct transcriptional pattern of DNA-pol genes across cancers, which highlighted the role of DNA-pol family genes in predicting the immunotherapy response for the first time, and TERT could be a novel vaccine candidate for improving immunotherapy response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
X. Bi, H. Zhao, Z. Luo.
Funding
Zhiwen Luo was awarded a funding for research in Israel (China Scholarship Council No. 202106210312). CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-C&T-B-043, 2021-I2M-C&T-B-052); Beijing CSCO Clinical Oncology Research Foundation (Y-XD202001-0111, Y-2019AZMS-0082, Y-XD202002-0370).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
197P - Clinical benefit of HER2-targeted therapies versus prior chemotherapy in refractory HER2 expressing and mutant gastrointestinal malignancies
Presenter: Vishesh Khanna
Session: Poster session 01
198P - Detection of ERBB2 (HER2) amplification by next-generation sequencing (NGS) in patients (pts) with gastrointestinal (GI) cancer
Presenter: Yunxiang Qi
Session: Poster session 01
199P - Novel machine learning (ML) algorithm to predict immunotherapy response in small cell (SCLC) and non-small cell (NSCLC) lung cancer
Presenter: Lakshya Sharma
Session: Poster session 01
200P - Precise tumor & patient selection for CDR404: A bispecific & bivalent MAGE-A4 T cell engager
Presenter: Giorgia Giacomazzi
Session: Poster session 01
201P - Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study
Presenter: Lore Decoster
Session: Poster session 01
202P - Participant perceptions and mammography adherence from DETECT-A: The first prospective interventional trial of a multi-cancer early detection (MCED) blood test
Presenter: Nicholas Papadopoulos
Session: Poster session 01
203P - Genomic characterization of sporadic MET amplified non-small cell lung cancer (NSCLC) and association with real-world outcomes
Presenter: Ryan Gentzler
Session: Poster session 01
204P - Performance assessment of a comprehensive genomic profiling (CGP) NGS kit across multiple study laboratories
Presenter: Jonathan Choi
Session: Poster session 01
205P - A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer
Presenter: Dorian Pamart
Session: Poster session 01
206P - WAYFIND-R: A global, real-world database of patients (pts) with a solid tumour profiled with next-generation sequencing (NGS)
Presenter: Jean-Yves Blay
Session: Poster session 01